Dexamethasone's Connection to COVID-19
DOI:
https://doi.org/10.15173/sciential.v1i9.3198Keywords:
COVID-19, Dexamethasone, Corticosteroid, Glucocorticoid, Recovery TrialAbstract
Dexamethasone is known for its use as an anti-inflammatory and immunosuppressant medication. This medication has been present for many years, and its benefits have been observed in the treatment of various conditions. With the rise of COVID-19 cases on an international scale, healthcare professionals globally searched for a therapeutic medication, either existing or under development that could help those who were ill with the virus. The Recovery Trial aims to find a pharmacotherapeutic medication that would assist in treating hospitalized individuals who were diagnosed with COVID-19. In this trial, Dexamethasone’s ability to reduce hospitalization durations, and patient fatality was observed. These results increased curiosity about Dexamethasone's potential in the fight against COVID-19. As we work towards a standardized treatment plan for COVID-19, investigate Dexame- thasone’s mechanisms of action, and how it impacts different populations; together, these findings may help to determine this medication’s effectiveness as a COVID-19 treatment option.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Sciential - McMaster Undergraduate Science Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors submitting to the journal must adhere to the terms of Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) license as outlined below:
1. You are free to share (copy and redistribute) any material from this journal, granted you have given appropriate credit, provided the link to the license, and indicated whether changes were applied to original work.
2. You are free to adapt (remix, transform, and build upon) any material from this journal, granted you distribute your work under the same license.
